Phase II Study of Preliminary Diagnostic Performance of [68Ga]-NeoBOMB1 in Adult Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Gallium 68 NeoBOMB1 (Primary)
- Indications Adenocarcinoma; Breast cancer; Carcinoma; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer
- Focus Diagnostic use
- Acronyms Neo-FIND
- Sponsors Advanced Accelerator Applications
- 22 Jul 2019 Status changed from active, no longer recruiting to completed.
- 19 Jul 2019 This trial has been discontinued in Austria
- 24 Jun 2019 Planned End Date changed from 1 Jun 2019 to 1 Jul 2019.